News
COPENHAGEN, Denmark, Jan. 7, 2025 /PRNewswire/ -- Vesper Bio ApS ('Vesper' or 'the ... today announces the initiation of a Phase Ib/IIa Proof of Concept (POC) study of its lead candidate VES001 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback